Survival in multiple myeloma has improved significantly with the advent of novel, more potent immunotherapies, including CAR ...

A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...

Anita D'Souza, MD, discusses an abstract looking at the combination of teclistamab-cqyv, daratumumab, and pomalidomide in 2 ...

Tony Newberne is a high-risk myeloma survivor. He is also a CPT, dietary manager, and patient advocate for several nonprofits ...

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

Study of frail older adult patients with myeloma showed reduced disease progression and death with a regimen reducing dexamethasone exposure.

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

Bispecific antibodies show strong initial uptake in community settings for multiple myeloma treatment, particularly among ...

Mansi Shah, MD, assistant professor, Rutgers Cancer Institute of New Jersey, shares long-term follow-up data on the efficacy ...

"This study provides strong evidence for the use of daratumumab as a treatment for high-risk smoldering multiple myeloma," says Dr. Rajkumar, the Edward W. and Betty Knight Scripps Professor of ...